JPRN-UMIN000030522招募中未知
A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies - Sirolimus for intractable vascular anomalies
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients who currently have an uncontrolled infection 2) Uncontrolled diabetes, uncontrolled hypertension, uncontrolled hyperlipidemia, chronic liver disease, or chronic renal disease 3) History of allergy to sirolimus, or additive substance 4) Known history of HIV seropositivity or known immunodeficiency 5) Patients who have undergone surgical resection or interventional radiology procedures for target lesions within 2 weeks 6) Pregnant, probably pregnant, or breast-feeding woman. Patients who do not agree birth control during clinical trial. 7) Patient who is judged inappropriate to participate in this study by the investigators
研究者
相似试验
进行中（未招募）
3 期
A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomaliesIntractable vascular anomaliesVascular disordersJPRN-jRCTs031180290Ozeki Michio130
进行中（未招募）
1 期
A multi-centre, open-label, single-arm study assessing the safety and efficacy of 5 mg of mifepristone for the treatment of endometriosis in reproductive-age women during two treatment cycles of 24 weeks eachendometriosis in reproductive-ageMedDRA version: 20.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2020-004302-63-HUitaphar Laboratorios S.L.300
进行中（未招募）
3 期
Efficacy and safety of Sirolimus granules twice daily administration in patients with intractuable vascular malformationsIntractable vascular malformationsVascular disordersD054079JPRN-jRCTs031200055Mochizuki Shinji11
尚未招募
4 期
A study of Romiplostim Powder for Injection in patientsCTRI/2021/08/035609Intas Pharmaceuticals Limited
尚未招募
4 期
The aim is to evaluate the safety and efficacy of MeRes100™ Sirolimus Eluting BioResorbable Vascular Scaffold in coronary artery disease patients.It enhances coronary luminal diameter in symptomatic ischemic heart disease, addressing de novo lesions in native coronary arteries.CTRI/2024/02/062438Meril Diagnostics Private Limited